单药抗程序性死亡受体-1(MDX-1106)治疗难治性实体瘤的I期研究:安全性、临床活性、药效动力学及免疫学相关性
39例晚期转移性黑色素瘤、结直肠癌、去势抵抗性前列腺癌、非小细胞肺癌或肾细胞癌患者接受单次静脉输注抗PD-1抗体MDX-1106,剂量递增为0.3、1、3或10 mg/kg六例队列,随后10 mg/kg扩展队列15例。抗PD-1耐受良好,观察到1例严重不良事件(炎性结肠炎);1例结直肠癌持续完全缓解,2例部分缓解(黑色素瘤、肾细胞癌);药效动力学显示PD-1占有持续>70%≥2个月。
要点
- 39例难治性实体瘤患者接受单次静脉抗PD-1(MDX-1106),剂量为0.3、1、3或10 mg/kg。
- 观察到1例严重不良事件为炎性结肠炎,发生于接受5次1 mg/kg剂量的黑色素瘤患者。
- 1例结直肠癌持续完全缓解,2例部分缓解(黑色素瘤、肾细胞癌)。
核心结论
- 间歇性抗体给药阻断PD-1免疫检查点耐受良好,并伴有抗肿瘤活性证据。
- 需要探索替代给药方案以及与疫苗、靶向治疗和/或其他检查点抑制剂的联合治疗。
研究设计与样本
- I期研究,39例晚期转移性黑色素瘤、结直肠癌、去势抵抗性前列腺癌、非小细胞肺癌或肾细胞癌患者。
- 剂量递增为六例队列,剂量为0.3、1、3或10 mg/kg,随后10 mg/kg扩展队列15例。
- 单次静脉输注抗PD-1(MDX-1106);3个月时有临床获益证据的患者有资格接受重复治疗。
主要发现
- 抗PD-1耐受良好:观察到1例严重不良事件(炎性结肠炎),发生于接受5次1 mg/kg剂量的黑色素瘤患者。
- 1例持续完全缓解(结直肠癌)和2例部分缓解(黑色素瘤、肾细胞癌)。
- 另外2例患者(黑色素瘤、非小细胞肺癌)有显著病灶肿瘤缩小但未达到部分缓解标准。
- 抗PD-1血清半衰期为12至20天。
- 药效动力学显示,无论剂量如何,输注后≥2个月循环T细胞上PD-1分子的平均占有持续>70%。
关键数值与推荐
- 剂量递增水平为0.3、1、3或10 mg/kg,扩展队列为10 mg/kg。
- 1例严重不良事件为炎性结肠炎,发生于接受5次1 mg/kg剂量的黑色素瘤患者。
- 抗PD-1血清半衰期为12至20天。
- 循环T细胞上PD-1分子平均占有持续>70%≥2个月,无论剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates. PATIENTS AND METHODS: Thirty-nine patients with advanced metastatic melanoma, colorectal cancer (CRC), castrate-resistant prostate cancer, non-small-cell lung cancer (NSCLC), or renal cell carcinoma (RCC) received a single intravenous infusion of anti-PD-1 (MDX-1106) in dose-escalating six-patient cohorts at 0.3, 1, 3, or 10 mg/kg, followed by a 15-patient expansion cohort at 10 mg/kg. Patients with evidence of clinical benefit at 3 months were eligible for repeated therapy. RESULTS: Anti-PD-1 was well tolerated: one serious adverse event, inflammatory colitis, was observed in a patient with melanoma who received five doses at 1 mg/kg. One durable complete response (CRC) and two partial responses (PRs; melanoma, RCC) were seen. Two additional patients (melanoma, NSCLC) had significant lesional tumor regressions not meeting PR criteria. The serum half-life of anti-PD-1 was 12 to 20 days. However, pharmacodynamics indicated a sustained mean occupancy of > 70% of PD-1 molecules on circulating T cells ≥ 2 months following infusion, regardless of dose. In nine patients examined, tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment. CONCLUSION: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity. Exploration of alternative dosing regimens and combinatorial therapies with vaccines, targeted therapies, and/or other checkpoint inhibitors is warranted.
引用
- Brahmer JR, Drake CG, Wollner I, et al. Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J Clin Oncol. 2023. PMID: 36706735. doi:10.1200/JCO.22.02270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。